Chugai Pharmaceutical Co., Ltd.
1Q Results (Jan 13 - Mar 13) Conference Call
April 25, 2013
- Font Size
-
- sm
- md
- lg
Chugai Pharmaceutical Co., Ltd.
- 1Q Results (Jan 13 - Mar 13) Conference Call
-
Yoshio Itaya
Executive Vice President CFO
Hisanori Takanashi
Department Manager of
Project Planning & Coordination Dept.
- FY2013 1Q Consolidated Financial Overview(IFRS based)
- presenter :
- Yoshio Itaya
Executive Vice President CFO
- Forward-Looking Statements
- Summary
- IFRS and Core Results
- Financial Overview Jan-Mar
- Sales (excl. Tamiflu) Jan-Mar
- Tamiflu Sales Performance
- Operating Profit Jan-Mar
- Financial Overview Jan-Mar
- Domestic Sales (excl. Tamiflu) Jan-Mar
- Impact from Foreign Exchange
- Overview of Development Pipeline
- presenter :
- Hisanori Takanashi
Department Manager of Project Planning & Coordination Dept.
- Development Status - Oncology
- Development Status - Autoimmune
- Actemra(R) Subcutaneous Formulation
- RG7414(parsatuzumab)- Augmenting Anti-VEGF Therapy
- RG7414(parsatuzumab) - Mode of Action
- Q&A
- Contacts
